Sagimet Biosciences (NasdaqGM:SGMT) 2026 Conference Transcript

Summary of Sagimet Biosciences Conference Call Company Overview - Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing FASN (fatty acid synthase) inhibitors for conditions such as MASH (metabolic dysfunction-associated steatotic liver disease), acne, and certain solid tumors. The lead program is denifanstat, which targets fat accumulation and related diseases [2][3] Key Points on MASH - Unique Mechanism: Denifanstat inhibits fat accumulation, inflammation, and fibrosis, distinguishing it from other treatments that primarily focus on fat burning [3][4] - Clinical Data: In a Phase 2 study, denifanstat showed significant fibrosis reduction in F2/F3 MASH patients, with 11 out of 13 F4 patients experiencing a one or two-stage improvement [5][4] - Future Studies: Plans to initiate a Phase 2 study focusing on F4 patients in combination with resmetirom, with no safety signals observed in prior studies [5][6] Key Points on Acne - Clinical Trials: Partner Ascletis completed Phase 2 and Phase 3 studies in China for moderate to severe acne, showing approximately 20% reduction in lesion count and improvement in IGA scores [6][11] - NDA Submission: Based on Phase 3 data, an NDA was submitted to the NMPA (Chinese FDA) and is currently under review [6][7] - Safety Profile: Denifanstat was well tolerated over 52 weeks, with minimal adverse events reported [7][13] Market Dynamics - Acne Treatment Landscape: The U.S. acne market affects about 50 million people, with a significant shift away from antibiotics due to resistance concerns. Denifanstat offers a novel mechanism of action that addresses sebum regulation, filling a gap in the current treatment options [15][19] - Regulatory Changes: Recent changes in guidelines by the AAD are pushing for reduced reliance on antibiotics, creating an opportunity for new treatments like denifanstat [15][18] Development of Next-Gen Molecule - TVB-3567: A next-generation FASN inhibitor is currently in Phase 1 trials, with a focus on safety and potential clinical activity. The goal is to confirm its efficacy in reducing sebum levels, which is crucial for acne treatment [20][26] - Commercial Strategy: The decision to advance TVB-3567 instead of denifanstat for acne is based on commercial considerations, including IP optimization and market positioning [20][22] Financial Outlook - Cash Position: As of Q3 earnings, Sagimet reported approximately $125 million in cash, expected to last until the end of 2027, supporting ongoing clinical trials and development efforts [62] Conclusion - Sagimet Biosciences is positioned to make significant advancements in the treatment of MASH and acne through its innovative FASN inhibitors. The company is on track to initiate further studies and has a solid financial foundation to support its development pipeline [63][62]